Heart risk from chemo: study stopped after just 2 patients
NCT ID NCT05803889
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to closely monitor heart function in women with breast cancer receiving common chemotherapy drugs (epirubicin, cyclophosphamide, paclitaxel) to see when heart damage first appears. Researchers planned to use advanced ultrasound and exercise tests to detect early changes. However, the study was terminated early with only 2 participants enrolled, so no meaningful conclusions could be drawn.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut de cancérologie Strasbourg Europe
Strasbourg, France, 67033, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?